ICU trades 126.6% below Wall Street's consensus target of $8.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ICU achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, SeaStar Medical Holding Corporation (ICU) has a Wall Street consensus price target of $8.00, based on estimates from 1 covering analysts. With the stock currently trading at $3.53, this represents a potential upside of +126.6%. The company has a market capitalization of $14M.
Analyst price targets range from a low of $8.00 to a high of $8.00, representing a 0% spread in expectations. The median target of $8.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ICU trades at a trailing P/E of -0.6x. Analysts expect EPS to grow -9.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NKTRNektar Therapeutics | $1.9B | $57.66 | $152.50 | +164.5% | Buy | — | 33 |
 TPVGTriplePoint Venture Growth BDC Corp. | $200M | $4.92 | $5.00 | +1.6% | Hold | 5.5x | 12 |
 AKBAAkebia Therapeutics, Inc. | $250M | $0.93 | $1.00 | +7.2% | Buy | — | 12 |
 CPRXCatalyst Pharmaceuticals, Inc. | $3.9B | $31.49 | $31.75 | +0.8% | Buy | 16.1x | 16 |
 XOMAXOMA Royalty Corp. | $504M | $40.17 | $39.00 | -2.9% | Buy | 51.2x | 10 |
 KRMDKORU Medical Systems, Inc. | $150M | $3.27 | $6.00 | +83.5% | Buy | — | 5 |
 PRAXPraxis Precision Medicines, Inc. | $7.9B | $282.12 | $603.83 | +114.0% | Buy | — | 18 |
 BAXBaxter International Inc. | $12.1B | $23.49 | $25.00 | +6.4% | Hold | 11.4x | 36 |
 DVADaVita Inc. | $11.8B | $183.14 | $235.67 | +28.7% | Hold | 12.3x | 23 |
 STESTERIS plc | $20.5B | $209.98 | $271.33 | +29.2% | Buy | 20.6x | 14 |
Quick answers to the most common questions about buying ICU stock.
The consensus Wall Street price target for ICU is $8, representing 126.6% upside from the current price of $3.53. With 1 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ICU has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $8 implies 126.6% upside from current levels.
ICU's current price is $3.53 with a consensus target of $8 (126.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $8 for ICU, while the most conservative target is $8. The consensus of $8 represents the median expectation. These targets typically reflect 12-month expectations.
ICU is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ICU stock forecast based on 1 Wall Street analysts shows a consensus price target of $8, with estimates ranging from $8 (bear case) to $8 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ICU, with a "Buy" consensus rating and $8 price target (126.6% upside). 1 of 1 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ICU analyst price targets range from $8 to $8, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.